Compliance - Certificate under Reg 74(5) of SEBI (DP) Regulations
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vista Pharmaceuticals has submitted a routine compliance certificate to BSE for the quarter ended 31 December 2025, confirming adherence to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, based on confirmation from the company's Registrar and Transfer Agent (Aarthi Consultants Private Limited), states that all physical share certificates received for dematerialisation during October–December 2025 were mutilated and cancelled within the required 15-day window, with the depository's name substituted as the registered owner in company records. It further confirms that the dematerialised securities remain listed on the stock exchange where the original shares were listed. The filing is signed by Executive Director Dhananjaya Alli.
This is a standard procedural compliance filing with no material impact on the company's financials, operations, or stock price. It merely confirms that share dematerialisation activities were handled properly during the quarter, indicating normal administrative functioning of the company's RTA.